Non-small cell lung cancer nonsquamous · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Vinorelbine (CVb) Variant #01 | — | R 3 333 | 21d | — | ~10.0 mo | ~7 | ~R 13 269 PFS proxy · indirect | 10 |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | ~5.0 mo | ~10.0 mo | ~4 | ~R 7 277 PFS proxy · indirect | 11 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | ~6.1 mo | ~14.2 mo | ~12 | ~R 12 296 PFS proxy · indirect | 7 |
3 of 3 regimens shown